First line therapy in Multiple Myeloma - Rabea, Ahmed
38,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
19 °P sammeln
  • Broschiertes Buch

In the past, survival in Multiple Myeloma was in the range of 1 to 3 years. With the introduction of the novel drugs as the immunomodulators (IMiDs) and Proteosome inhibitors, survival has markedly increased and quality of life has improved. In this book, I have given an overview of the novel drugs and their use as first line therapy in multiple myeloma aiming for better prognosis, survival and quality of life.

Andere Kunden interessierten sich auch für
Produktbeschreibung
In the past, survival in Multiple Myeloma was in the range of 1 to 3 years. With the introduction of the novel drugs as the immunomodulators (IMiDs) and Proteosome inhibitors, survival has markedly increased and quality of life has improved. In this book, I have given an overview of the novel drugs and their use as first line therapy in multiple myeloma aiming for better prognosis, survival and quality of life.
Autorenporträt
Oncology Specialist, Assistant Lecturer of Medical Oncology, National Cancer Institite, Cairo University, Egypt. Clinical Fellow of Hemato-oncology, Princess Margaret Hospital, Toronto, Canada. Master Degree student in Advanced Oncology, Ulm University, Germany.